(doravirine + lamivudine + tenofovir disoproxil fumarate)
Marketedupdated 2mo agoby Merck Sharp & Dohme Corp (Inactive)
Approvedcommunity read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 1 investigational indication.
all catalysts(7)
approval · 7
Aug 30, 2018
approval
DELSTRIGO (DORAVIRINE) — FDA approval
(doravirine + lamivudine + tenofovir disoproxil fumarate)
→
Sep 19, 2019
approval
DELSTRIGO (DORAVIRINE) — FDA approval
(doravirine + lamivudine + tenofovir disoproxil fumarate)
→
Oct 10, 2019
approval
DELSTRIGO (DORAVIRINE) — FDA approval
(doravirine + lamivudine + tenofovir disoproxil fumarate)
→
Jan 27, 2022
approval
DELSTRIGO (DORAVIRINE) — FDA approval
(doravirine + lamivudine + tenofovir disoproxil fumarate)
→
Nov 7, 2024
approval
DELSTRIGO (DORAVIRINE) — FDA approval
(doravirine + lamivudine + tenofovir disoproxil fumarate)
→
Jun 12, 2025
approval
DELSTRIGO (DORAVIRINE) — FDA approval
(doravirine + lamivudine + tenofovir disoproxil fumarate)
→
Oct 29, 2025
approval
DELSTRIGO (DORAVIRINE) — FDA approval
(doravirine + lamivudine + tenofovir disoproxil fumarate)
→
News(0)
no news has mentioned this drug yet
comments(0)
5-min edit window · permanent after that